Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Accumulated Expenses (2017 - 2025)

Serina Therapeutics (SER) has disclosed Other Accumulated Expenses for 6 consecutive years, with $337000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 74.61% to $337000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $337000.0 through Dec 2025, up 74.61% year-over-year, with the annual reading at $337000.0 for FY2025, 74.61% up from the prior year.
  • Other Accumulated Expenses hit $337000.0 in Q4 2025 for Serina Therapeutics, down from $350000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $545000.0 in Q2 2025 to a low of $5000.0 in Q2 2024.
  • Historically, Other Accumulated Expenses has averaged $220333.3 across 4 years, with a median of $195500.0 in 2024.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 97.83% in 2024 and later surged 10800.0% in 2025.
  • Year by year, Other Accumulated Expenses stood at $141000.0 in 2022, then soared by 77.3% to $250000.0 in 2023, then dropped by 22.8% to $193000.0 in 2024, then surged by 74.61% to $337000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for SER at $337000.0 in Q4 2025, $350000.0 in Q3 2025, and $545000.0 in Q2 2025.